Loading stock data…
NOVARTIS N (NOVN.SW)
CHF 123.74-0.90 (-0.72%)
Market ClosedLast close Aug 28
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Novartis AG in the Healthcare sector is trading at $123.74 with a market capitalization of $232.7B. Wall Street consensus targets $124.89 (21 analysts), implying a +0.9% move over the next 12 months. The stock is currently 6% below its 52-week high of $131.50, remaining 6.0% above its 200-day moving average. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | $14.84B↑ | $14.36B↑ | $13.86B↑ | $13.52B↓ | $14.95B |
| Gross Profit | $11.51B↑ | $10.82B↑ | $10.25B↑ | $10.06B↓ | $11.24B |
| Operating Income | $4.86B↑ | $4.50B↑ | $3.62B↓ | $4.24B↓ | $4.75B |
| Net Income | $4.04B↑ | $3.93B↑ | $2.41B↓ | $3.16B↓ | $3.26B |
Peer Comparison
JNJUNHPFE
Fundamentals
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart f...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$232.72B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
22.80
Beta
Defensive asset. Lower volatility than the S&P 500.
0.49
Div Yield
Strong income play. Yield provides a meaningful total return floor.
299.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
30.35%
Volume
Today's trading volume
1.96M
Recent News
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
IBRX Stock Extends 3-Day Slide — Founder Teases New Trial In ‘Unstoppable’ Cancer-Treatment Push
Soon-Shiong teased a trial pairing Pluvicto’s targeted radiation with an IL-15-based immune treatment.
VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
Vanguard offers three dividend ETFs—VIG, VYM, and VYMI—with distinct yields, holdings, and geographic focus, giving income investors varied ways to access dividend-paying stocks.
Sustainable Development ETF (SDG) Touches New 52-Week High
SDG hits a 52-week high as strong earnings from top holdings and institutional ESG inflows fuel momentum, with alpha signaling more gains.